| Year |
Citation |
Score |
| 2024 |
Morrow WP, Milligan NS, Ohgami RS, Young KH, Wang B, Vega F, Marques-Piubelli ML, Feldman AL, Slack GW, Savage KJ, Zhao X, Rubenstein JL, Hsi ED. Clinicopathologic features of primary central nervous system anaplastic large cell lymphoma: a multicenter study identifies age and ALK status as prognostic factors. Journal of Hematopathology. PMID 39549220 DOI: 10.1007/s12308-024-00612-8 |
0.342 |
|
| 2024 |
Batchelor TT, Giri S, Ruppert AS, Geyer S, Smith SE, Mohile N, Swinnen LJ, Friedberg JW, Kahl BS, Bartlett NL, Hsi ED, Cheson BD, Wagner-Johnston ND, Nayak L, Leonard JP, ... Rubenstein JL, et al. Myeloablative Vs. Non-Myeloablative Consolidation for Primary Central Nervous System Lymphoma: Results of Alliance 51101. Blood Advances. PMID 38598710 DOI: 10.1182/bloodadvances.2023011657 |
0.347 |
|
| 2023 |
David KA, Sundaram S, Kim SH, Vaca R, Lin Y, Singer S, Malecek MK, Carter J, Zayac A, Kim MS, Reddy N, Ney D, Habib A, Strouse C, Graber J, ... ... Rubenstein J, et al. Older Patients with Primary Central Nervous System Lymphoma: Survival and Prognostication Across 20 US Cancer Centers. American Journal of Hematology. PMID 36965007 DOI: 10.1002/ajh.26919 |
0.306 |
|
| 2023 |
Wu SY, Braunstein SE, Rubenstein JL, Sneed PK. Stereotactic Radiosurgery for Primary Central Nervous System Lymphoma. Cureus. 15: e34817. PMID 36915845 DOI: 10.7759/cureus.34817 |
0.333 |
|
| 2022 |
Goyal V, Salmasi G, Leavitt AD, Rubenstein JL, Banerjee R. Acquired factor VII inhibitor associated with primary central nervous system Lymphoma: A case report. Ejhaem. 3: 1000-1002. PMID 36051043 DOI: 10.1002/jha2.482 |
0.341 |
|
| 2021 |
Chan JP, Merlini M, Gao HX, Mendiola AS, Akassoglou K, Rubenstein JL, Ryu JK. Blood Coagulation Factor Fibrinogen in Tumor Pathogenesis of Central Nervous System B-Cell Lymphoma. The American Journal of Pathology. 191: 575-583. PMID 33608067 DOI: 10.1016/j.ajpath.2020.12.010 |
0.372 |
|
| 2020 |
Wu CH, Yang CY, Wang L, Gao HX, Rakhshandehroo T, Afghani S, Pincus L, Balassanian R, Rubenstein J, Gill R, Bandyopadhyay S, McCormick F, Moasser M, Ai WZ. Cutaneous T cell lymphoma PDX drug screening platform identifies cooperation between inhibitions of PI3Kα/δ and HDAC. The Journal of Investigative Dermatology. PMID 32603749 DOI: 10.1016/J.Jid.2020.05.110 |
0.369 |
|
| 2020 |
Tsang M, Cleveland J, Rubenstein JL. On Point in Primary CNS Lymphoma. Hematological Oncology. PMID 32510610 DOI: 10.1002/Hon.2761 |
0.427 |
|
| 2020 |
Batchelor T, Giri S, Ruppert AS, Bartlett NL, Hsi ED, Cheson BD, Nayak L, Leonard JP, Rubenstein JL. Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101. Journal of Clinical Oncology. 38: 8042-8042. DOI: 10.1200/Jco.2020.38.15_Suppl.8042 |
0.468 |
|
| 2019 |
Ferreri AJM, Holdhoff M, Nayak L, Rubenstein JL. Evolving Treatments for Primary Central Nervous System Lymphoma. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 454-466. PMID 31099614 DOI: 10.1200/EDBK_242547 |
0.421 |
|
| 2019 |
Rubenstein JL, Geng H, Vu K, Mannis G, Formaker P, Hwang J, Munster PN, Damato B. Maintenance Lenalidomide in Primary CNS Lymphoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 31046114 DOI: 10.1093/Annonc/Mdz142 |
0.461 |
|
| 2019 |
Vu K, Mannis G, Hwang J, Geng H, Rubenstein JL. Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma. British Journal of Haematology. PMID 30714128 DOI: 10.1111/Bjh.15787 |
0.434 |
|
| 2019 |
Damato BE, Bever GJ, Afshar AR, Rubenstein JL. Insights from a Case of Vitreoretinal Lymphoma. Ocular Oncology and Pathology. 5: 13-19. PMID 30675472 DOI: 10.1159/000487949 |
0.389 |
|
| 2019 |
Solomon DA, Geng H, Sobel RA, Subbaraj L, Tsang M, Rubenstein JL. Potential Genetic and Immunologic Mechanisms of Therapeutic Resistance and Disease Progression in CNS Lymphoma Elucidated Via Whole Brain Autopsy Studies Blood. 134: 1494-1494. DOI: 10.1182/Blood-2019-131302 |
0.439 |
|
| 2019 |
WU C, Yang C, Wang L, Gao H, Taha R, Afghani S, Pincus L, Balassanian R, Rubenstein J, Gill R, Bandyopadhyay S, McCormick F, Moasser M, Ai WZ. Development of a Pathway-Directed Drug Screen Platform for Cutaneous T Cell Lymphoma Using Patient-Derived Xenograft Models Blood. 134: 1578-1578. DOI: 10.1182/Blood-2019-122589 |
0.367 |
|
| 2018 |
Grommes C, Rubenstein JL, DeAngelis LM, Ferreri AJM, Batchelor TT. Comprehensive Approach to Diagnosis and Treatment of Newly Diagnosed Primary CNS Lymphoma. Neuro-Oncology. PMID 30418592 DOI: 10.1093/Neuonc/Noy192 |
0.481 |
|
| 2018 |
Rubenstein JL. Can rituximab unlock the innate potential of checkpoint blockade in the CNS? Leukemia & Lymphoma. 1-3. PMID 30188237 DOI: 10.1080/10428194.2018.1510496 |
0.303 |
|
| 2018 |
Rubenstein JL, Geng H, Fraser EJ, Formaker P, Chen L, Sharma J, Killea P, Choi K, Ventura J, Kurhanewicz J, Lowell C, Hwang J, Treseler P, Sneed PK, Li J, et al. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Advances. 2: 1595-1607. PMID 29986852 DOI: 10.1182/Bloodadvances.2017014845 |
0.729 |
|
| 2018 |
Geng H, Tiret B, Gao H, Kadoch C, Lu M, Chen L, Park I, Melkus G, Elkhaled A, Kurhanewicz J, Drew L, Degorce S, Mayo M, Dillman K, Anjum R, ... ... Rubenstein J, et al. Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NFkB Activation in Preclinical Patient-Derived Models of CNS Lymphoma Blood. 132: 2840-2840. DOI: 10.1182/Blood-2018-99-117625 |
0.433 |
|
| 2018 |
Vu K, Rubenstein J, Mannis GN, Hwang J, Geng H. Low-Dose Lenalidomide Maintenance after Induction Therapy in Older Patients with Primary CNS Lymphoma Blood. 132: 4230-4230. DOI: 10.1182/Blood-2018-99-112767 |
0.432 |
|
| 2018 |
Subbaraj L, Geng H, Sharma J, LaFontaine M, Rubenstein JL. Abstract 4975: Tumor metabolism and cognitive dysfunction in CNS lymphoma Cancer Research. 78: 4975-4975. DOI: 10.1158/1538-7445.Am2018-4975 |
0.331 |
|
| 2018 |
Wu S, Braunstein S, Rubenstein J, Sneed P. Rthp-31. Stereotactic Radiosurgery For Primary Central Nervous System Lymphoma Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.961 |
0.456 |
|
| 2017 |
Rubenstein JL. Biology of CNS lymphoma and the potential of novel agents. Hematology. American Society of Hematology. Education Program. 2017: 556-564. PMID 29222305 DOI: 10.1182/Asheducation-2017.1.556 |
0.466 |
|
| 2017 |
Bever GJ, Kim DJ, Afshar AR, Rubenstein JL, Damato BE. THERAPEUTIC VITRECTOMY AS AN ADJUNCT TREATMENT TO SYSTEMIC CHEMOTHERAPY FOR INTRAOCULAR LYMPHOMA. Retinal Cases & Brief Reports. PMID 29210961 DOI: 10.1097/Icb.0000000000000668 |
0.354 |
|
| 2017 |
Gupta NK, Wang CC, Mannis GN, Yu JJ, Rubenstein JL. Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy. Leukemia & Lymphoma. 1-4. PMID 28395565 DOI: 10.1080/10428194.2017.1312374 |
0.389 |
|
| 2017 |
Tiret B, Autry A, Park I, Lu M, Anjum R, Drew L, Degorce S, Mayo M, Dillman K, Rubenstein J, Chaumeil MM. Exth-71. Hyperpolarized [1-13C] Pyruvate As A Biomarker For Treatment Monitoring In Lymphoma Murine Models Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.362 |
0.3 |
|
| 2017 |
Nayak L, Iwamoto FM, Ferreri AJ, Santoro A, Singer S, Batlevi C, Batchelor T, Rubenstein J, Johnston P, Ramchandren R, Soussain C, Drappatz J, Becker K, Witzens-Harig M, Illerhaus G, et al. Checkmate 647: A Phase 2, Open‐Label Study Of Nivolumab In Relapsed/Refractory Primary Central Nervous System Lymphoma Or Relapsed/Refractory Primary Testicular Lymphoma Hematological Oncology. 35: 420-421. DOI: 10.1002/Hon.2440_2 |
0.475 |
|
| 2017 |
Rubenstein JL, Hwang J, Mannis G. Preliminary analysis of lenalidomide maintenance after methotrexate-temozolomide-rituximab induction in older patients with PCNSL Hematological Oncology. 35: 343-344. DOI: 10.1002/Hon.2439_91 |
0.32 |
|
| 2016 |
Carnevale J, Rubenstein JL. The Challenge of Primary Central Nervous System Lymphoma. Hematology/Oncology Clinics of North America. 30: 1293-1316. PMID 27888882 DOI: 10.1016/J.Hoc.2016.07.013 |
0.48 |
|
| 2016 |
Gupta NK, Nolan A, Omuro A, Reid EG, Wang CC, Mannis G, Jaglal M, Chavez JC, Rubinstein PG, Griffin A, Abrams DI, Hwang J, Kaplan LD, Luce JA, Volberding P, ... ... Rubenstein JL, et al. Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro-Oncology. PMID 27576871 DOI: 10.1093/Neuonc/Now155 |
0.45 |
|
| 2016 |
Kasenda B, Loeffler J, Illerhaus G, Ferreri AJ, Rubenstein J, Batchelor TT. The role of whole brain radiation in primary CNS lymphoma. Blood. PMID 27207798 DOI: 10.1182/Blood-2016-01-650101 |
0.495 |
|
| 2016 |
Korfel A, Chamberlain M, Neuwelt E, Thiel E, Doolittle N, Schlegel U, Dreyling M, Rubenstein J, Fischer L, Björkholm M, Martus P, Weller M, Glantz M. Therapy for Secondary CNS Involvement in Malignant Lymphomas: No Standard Yet! Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 1829-30. PMID 27001566 DOI: 10.1200/Jco.2015.65.0879 |
0.434 |
|
| 2016 |
Rubenstein JL, Fraser E, Formaker P, Lee JC, Chen N, Kock M, Cheung W, Wang X, Munster PN, Damato B. Phase I investigation of lenalidomide plus rituximab and outcomes of lenalidomide maintenance in recurrent CNS lymphoma. Journal of Clinical Oncology. 34: 7502-7502. DOI: 10.1200/Jco.2016.34.15_Suppl.7502 |
0.703 |
|
| 2016 |
Geng H, Gao H, Kadoch C, Lu M, Chen L, Anjum R, Drew L, Degorce S, Dillman K, Mayo M, Anderson S, Collins C, Lowell CA, Rubenstein JL. Targeting NF-KB Activation in Novel Intracranial Models of CNS Lymphoma Blood. 128: 777-777. DOI: 10.1182/Blood.V128.22.777.777 |
0.447 |
|
| 2016 |
Ai W, Yang YY, Afghani S, Gao H, Pincus LP, Wang LW, Rakhshandhroo T, Balassanian R, Rubenstein J, Gill R, McCormick F. Abstract A06: Development of a drug discovery platform using clinically relevant patient-derived xenograft models for cutaneous T cell lymphomas Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-A06 |
0.372 |
|
| 2016 |
Rubenstein J, Fraser E, Formaker P, Lee JC, Chen N, Kock M, Cheung W, Killea P, Choi K, Wang X, Munster P, Damato B. Atim-27. Phase I Investigation Of Lenalidomide Plus Rituximab And Outcomes Of Lenalidomide Maintenance In Recurrent Cns Lymphoma Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.092 |
0.672 |
|
| 2015 |
Mabray MC, Cohen BA, Villanueva-Meyer JE, Valles FE, Barajas RF, Rubenstein JL, Cha S. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms. Ajr. American Journal of Roentgenology. 205: 1075-85. PMID 26496556 DOI: 10.2214/Ajr.14.13970 |
0.359 |
|
| 2015 |
Shalabi H, Angiolillo A, Vezina G, Rubenstein JL, Pittaluga S, Raffeld M, Marcus L. Prolonged Complete Response in a Pediatric Patient With Primary Peripheral T-Cell Lymphoma of the Central Nervous System. Pediatric Hematology and Oncology. 1-6. PMID 26384083 DOI: 10.3109/08880018.2015.1074325 |
0.445 |
|
| 2015 |
Mabray MC, Barajas RF, Villanueva-Meyer JE, Zhang CA, Valles FE, Rubenstein JL, Cha S. The Combined Performance of ADC, CSF CXC Chemokine Ligand 13, and CSF Interleukin 10 in the Diagnosis of Central Nervous System Lymphoma. Ajnr. American Journal of Neuroradiology. PMID 26381553 DOI: 10.3174/Ajnr.A4450 |
0.385 |
|
| 2015 |
Fraser E, Gruenberg K, Rubenstein JL. New approaches in primary central nervous system lymphoma. Chinese Clinical Oncology. 4: 11. PMID 25841718 DOI: 10.3978/J.Issn.2304-3865.2015.02.01 |
0.723 |
|
| 2015 |
Okimoto RA, Perry A, Rubenstein JL. 77-year-old woman with a dural-based mass. Marginal zone B-cell lymphoma (MZBCL). Brain Pathology (Zurich, Switzerland). 25: 111-2. PMID 25521182 DOI: 10.1111/Bpa.12233 |
0.331 |
|
| 2015 |
Mahajan A, Ho S, Lo M, Rubenstein JL, Fong R. Frequency, Risk Factors and Mortality Effect of Venous Thromboembolism in Adult Patients with Central Nervous System Lymphoma Blood. 126: 4458-4458. DOI: 10.1182/Blood.V126.23.4458.4458 |
0.448 |
|
| 2015 |
Geng H, Chen Z, Anderson S, Fraser E, Lu M, Lingjing C, Collins C, Markus M, Rubenstein JL. Expression of B and T Lymphocyte Attenuator (BTLA) Correlates with CNS Metastasis and Adverse Prognosis in Activated B-Cell Lymphoma and Acute Lymphoblastic Leukemia Blood. 126: 3900-3900. DOI: 10.1182/Blood.V126.23.3900.3900 |
0.712 |
|
| 2014 |
Wang CC, Carnevale J, Rubenstein JL. Progress in central nervous system lymphomas. British Journal of Haematology. 166: 311-25. PMID 24837460 DOI: 10.1111/Bjh.12938 |
0.495 |
|
| 2014 |
Ponzoni M, Issa S, Batchelor TT, Rubenstein JL. Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 316-22. PMID 24265352 DOI: 10.1093/Annonc/Mdt385 |
0.461 |
|
| 2014 |
Kadoch C, Li J, Wong VS, Chen L, Cha S, Munster P, Lowell CA, Shuman MA, Rubenstein JL. Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1029-41. PMID 24190981 DOI: 10.1158/1078-0432.Ccr-13-0474 |
0.403 |
|
| 2014 |
Rubenstein JL, Formaker P, Wang X, Chen N, Seider M, Munster P, Damato B. Interim Results of a Phase I Study of Lenalidomide (CC-5013) Plus Intraventricular/Intravenous Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma Blood. 124: 4470-4470. DOI: 10.1182/Blood.V124.21.4470.4470 |
0.511 |
|
| 2013 |
Rubenstein JL, Gupta NK, Mannis GN, Lamarre AK, Treseler P. How I treat CNS lymphomas. Blood. 122: 2318-30. PMID 23963042 DOI: 10.1182/Blood-2013-06-453084 |
0.496 |
|
| 2013 |
Rubenstein JL, Wong VS, Kadoch C, Gao HX, Barajas R, Chen L, Josephson SA, Scott B, Douglas V, Maiti M, Kaplan LD, Treseler PA, Cha S, Hwang JH, Cinque P, et al. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood. 121: 4740-8. PMID 23570798 DOI: 10.1182/Blood-2013-01-476333 |
0.392 |
|
| 2013 |
Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, Cheson BD, Kaplan LD. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3061-8. PMID 23569323 DOI: 10.1200/Jco.2012.46.9957 |
0.458 |
|
| 2013 |
Scott BJ, Douglas VC, Tihan T, Rubenstein JL, Josephson SA. A systematic approach to the diagnosis of suspected central nervous system lymphoma. Jama Neurology. 70: 311-9. PMID 23319132 DOI: 10.1001/Jamaneurol.2013.606 |
0.415 |
|
| 2013 |
Rubenstein JL, Li J, Chen L, Advani R, Drappatz J, Gerstner E, Batchelor T, Krouwer H, Hwang J, Auerback G, Kadoch C, Lowell C, Munster P, Cha S, Shuman MA, et al. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 121: 745-51. PMID 23197589 DOI: 10.1182/Blood-2012-07-440974 |
0.512 |
|
| 2013 |
Valles FE, Perez-Valles CL, Regalado S, Barajas RF, Rubenstein JL, Cha S. Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immunocompetent patients with primary central nervous system lymphoma. Ajnr. American Journal of Neuroradiology. 34: 35-40. PMID 22936096 DOI: 10.3174/Ajnr.A3165 |
0.376 |
|
| 2013 |
Wang CJ, Bracci PM, Rubenstein JL. Obesity and Hepatitis B Infection and Risk Of Primary CNS Lymphoma Blood. 122: 4298-4298. DOI: 10.1182/Blood.V122.21.4298.4298 |
0.329 |
|
| 2013 |
Hwang J, Rubenstein JL. High-Dose Methotrexate Is Effective, Safe, and Leads To Durable Responses In Patients With AIDS-Related Primary Central Nervous System Lymphoma Treated During The Era Of Combined Anti-Retroviral Therapy Blood. 122: 1792-1792. DOI: 10.1182/Blood.V122.21.1792.1792 |
0.441 |
|
| 2012 |
Wieduwilt MJ, Valles F, Issa S, Behler CM, Hwang J, McDermott M, Treseler P, O'Brien J, Shuman MA, Cha S, Damon LE, Rubenstein JL. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1146-55. PMID 22228634 DOI: 10.1158/1078-0432.Ccr-11-0625 |
0.473 |
|
| 2012 |
Rubenstein JL, Hsi ED, Johnson JL, Jung S, Grant B, Cheson BD, Kaplan LD. BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance) Blood. 120: 301-301. DOI: 10.1182/Blood.V120.21.301.301 |
0.497 |
|
| 2012 |
Rubenstein JL. Biology of primary central nervous system lymphoma Lymphoma and Leukemia of the Nervous System. 99-111. DOI: 10.1007/9781441976680_5 |
0.35 |
|
| 2011 |
Chan CC, Rubenstein JL, Coupland SE, Davis JL, Harbour JW, Johnston PB, Cassoux N, Touitou V, Smith JR, Batchelor TT, Pulido JS. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. The Oncologist. 16: 1589-99. PMID 22045784 DOI: 10.1634/Theoncologist.2011-0210 |
0.517 |
|
| 2011 |
Rubenstein JL, Treseler PA, Stewart PJ. Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e595-7. PMID 21519022 DOI: 10.1200/Jco.2011.34.7252 |
0.391 |
|
| 2011 |
Bet-Lachin A, Jiang F, Chen L, Keshari K, Wilson D, Kurhanewicz J, Rubenstein JL. Metabolic Profiling of CNS Lymphoma and Its Microenvironment Blood. 118: 588-588. DOI: 10.1182/Blood.V118.21.588.588 |
0.377 |
|
| 2011 |
Gao H, Anderson S, Chen L, Kadoch C, Hann BC, Lowell C, Collins C, Rubenstein JL. Genomic and Molecular Properties of Relapsed CNS Lymphoma Using Novel Primary Meningeal Lymphoma Cell Lines and Intracranial Xenografts, Blood. 118: 3477-3477. DOI: 10.1182/Blood.V118.21.3477.3477 |
0.49 |
|
| 2011 |
Kadoch C, Wong V, Chen L, Bet-Lachin A, Roy R, Hyun W, Behler C, Lowell C, Rubenstein JL. Dynamic Changes in Macrophage Polarization Correlate with Progression and Response in CNS Lymphoma: Insights Into the Transcriptome of Lymphoma-Associated M2 Macrophages, Blood. 118: 3219-3219. DOI: 10.1182/Blood.V118.21.3219.3219 |
0.353 |
|
| 2011 |
Valles F, Regalado S, Rubenstein JL, Cha S. Combined Diffusion and Perfusion MRI As Biomarkers of Prognosis in Immunocompetent Patients with Primary CNS Lymphoma Blood. 118: 2655-2655. DOI: 10.1182/Blood.V118.21.2655.2655 |
0.414 |
|
| 2010 |
Barajas RF, Rubenstein JL, Chang JS, Hwang J, Cha S. Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. Ajnr. American Journal of Neuroradiology. 31: 60-6. PMID 19729544 DOI: 10.3174/Ajnr.A1750 |
0.415 |
|
| 2010 |
Rubenstein JL, Kadoch C, Wong VS, Hyun W, Lowell C. Interim results of a phase I trial of intraventricular rituximab plus methotrexate in recurrent CNS lymphoma: Macrophage polarization and acquired resistance to therapy. Journal of Clinical Oncology. 28: 2532-2532. DOI: 10.1200/Jco.2010.28.15_Suppl.2532 |
0.433 |
|
| 2010 |
Rubenstein JL, Johnson JL, Jung S, Cheson BD, Kaplan LD. Intensive Chemotherapy and Immunotherapy, without Brain Irradiation, In Newly Diagnosed Patients with Primary CNS Lymphoma: Results of CALGB 50202 Blood. 116: 763-763. DOI: 10.1182/Blood.V116.21.763.763 |
0.468 |
|
| 2010 |
Kadoch C, Wong VS, Rambaldo TC, Hyun WC, Gao HX, Lowell CA, Rubenstein JL. Abstract 5580: Macrophage polarization and acquired resistance to rituximab in CNS lymphoma Cancer Research. 70: 5580-5580. DOI: 10.1158/1538-7445.Am10-5580 |
0.341 |
|
| 2010 |
Wong VS, Chen L, Kadoch C, Tsang A, Siu L, Lowell C, Rubenstein JL. Abstract 2728: Multivariate analysis of cerebrospinal fluid protein biomarkers in central nervous system lymphoma patients and controls Cancer Research. 70: 2728-2728. DOI: 10.1158/1538-7445.Am10-2728 |
0.451 |
|
| 2009 |
Algazi AP, Kadoch C, Rubenstein JL. Biology and treatment of primary central nervous system lymphoma. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 6: 587-97. PMID 19560747 DOI: 10.1016/J.Nurt.2009.04.013 |
0.476 |
|
| 2009 |
Kadoch C, Dinca EB, Voicu R, Chen L, Nguyen D, Parikh S, Karrim J, Shuman MA, Lowell CA, Treseler PA, James CD, Rubenstein JL. Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1989-97. PMID 19276270 DOI: 10.1158/1078-0432.Ccr-08-2054 |
0.452 |
|
| 2009 |
Rubenstein JL, Shen A, Batchelor TT, Kadoch C, Treseler P, Shuman MA. Differential gene expression in central nervous system lymphoma. Blood. 113: 266-7; author reply . PMID 19122120 DOI: 10.1182/Blood-2008-04-152835 |
0.405 |
|
| 2009 |
Mrugala MM, Rubenstein JL, Ponzoni M, Batchelor TT. Insights into the biology of primary central nervous system lymphoma. Current Oncology Reports. 11: 73-80. PMID 19080745 DOI: 10.1007/S11912-009-0012-8 |
0.411 |
|
| 2009 |
Yang I, Delpolyi A, Sughrue ME, Rubenstein J, Bollen AW, Parsa AT. Sarcoidosis of the pineal gland: an unusual presentation of neurosarcoidosis. Journal of Neuro-Oncology. 91: 113-6. PMID 18759061 DOI: 10.1007/S11060-008-9687-1 |
0.343 |
|
| 2009 |
Kadoch C, Wong VD, Rambaldo T, Hyun W, Lowell C, Rubenstein J. Macrophage Polarization and Acquired Resistance to Rituximab in CNS Lymphoma. Blood. 114: 3749-3749. DOI: 10.1182/Blood.V114.22.3749.3749 |
0.345 |
|
| 2008 |
Grimm SA, McCannel CA, Omuro AM, Ferreri AJ, Blay JY, Neuwelt EA, Siegal T, Batchelor T, Jahnke K, Shenkier TN, Hall AJ, Graus F, Herrlinger U, Schiff D, Raizer J, ... Rubenstein J, et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology. 71: 1355-60. PMID 18936428 DOI: 10.1212/01.Wnl.0000327672.04729.8C |
0.477 |
|
| 2008 |
Rubenstein J, Ferreri AJ, Pittaluga S. Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leukemia & Lymphoma. 49: 43-51. PMID 18821432 DOI: 10.1080/10428190802311441 |
0.45 |
|
| 2008 |
Damon L, Damon LE, Gaensler K, Kaplan L, Martin T, Rubenstein J, Linker C. Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma. Bone Marrow Transplantation. 42: 649-57. PMID 18679366 DOI: 10.1038/Bmt.2008.236 |
0.384 |
|
| 2008 |
Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL. Protein biomarker identification in the CSF of patients with CNS lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 96-105. PMID 18056677 DOI: 10.1200/Jco.2007.12.1053 |
0.394 |
|
| 2008 |
Scearce-Levie K, Roberson ED, Gerstein H, Cholfin JA, Mandiyan VS, Shah NM, Rubenstein JL, Mucke L. Abnormal social behaviors in mice lacking Fgf17. Genes, Brain, and Behavior. 7: 344-54. PMID 17908176 DOI: 10.1111/j.1601-183X.2007.00357.x |
0.405 |
|
| 2007 |
Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, Issa S, Damon L, Prados M, McDermott M, O'Brien J, Haqq C, Shuman M. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 1350-6. PMID 17312328 DOI: 10.1200/Jco.2006.09.7311 |
0.425 |
|
| 2007 |
Kadoch C, Shuman MA, Rubenstein JL. Complement Activation and Resistance within the Cerebrospinal Fluid Following Intraventricular Administration of Anti-CD20 in the Treatment of Recurrent CNS Lymphoma. Blood. 110: 3418-3418. DOI: 10.1182/Blood.V110.11.3418.3418 |
0.393 |
|
| 2007 |
Issa S, Shen A, Karch J, Kadoch C, Shuman M, Damon L, Rubenstein J. Treatment of Primary CNS Lymphoma with Induction High-Dose Methotrexate, Temozolomide, Rituximab Followed by Consolidation Cytarabine/Etoposide: A Pilot Study with Biomarker Analysis. Blood. 110: 1364-1364. DOI: 10.1182/Blood.V110.11.1364.1364 |
0.478 |
|
| 2006 |
Kadoch C, Treseler P, Rubenstein JL. Molecular pathogenesis of primary central nervous system lymphoma. Neurosurgical Focus. 21: E1. PMID 17134111 DOI: 10.3171/Foc.2006.21.5.2 |
0.51 |
|
| 2006 |
Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, Karch J, Okada C, Hyun W, Parikh S, Haqq C, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood. 107: 3716-23. PMID 16418334 DOI: 10.1182/Blood-2005-03-0897 |
0.482 |
|
| 2006 |
Orr JW, Dosoretz DD, Mahoney D, Roland PY, Kelly FJ, Blitzer P, Nakfoor B, Katin M, Rubenstein J, Boothby RR. Surgically (laparotomy/laparoscopy) guided placement of high dose rate interstitial irradiation catheters (LG-HDRT): technique and outcome. Gynecologic Oncology. 100: 145-8. PMID 16249021 DOI: 10.1016/J.Ygyno.2005.08.055 |
0.366 |
|
| 2006 |
Issa S, Hwang J, Karch J, Fridlyand J, Prados M, Batchelor T, Aldape K, Haqq C, Damon L, Rubenstein J. Treatment of primary CNS lymphoma with induction high-dose methotrexate, temozolomide, rituximab followed by consolidation cytarabine/etoposide: A pilot study with biomarker analysis Journal of Clinical Oncology. 24: 7595-7595. DOI: 10.1200/Jco.2006.24.18_Suppl.7595 |
0.442 |
|
| 2006 |
Rubenstein JL, Kadoch C, Karch J, Josephson A, Issa S, Becker C, Schulman H, Damon L, Shuman MA, Roy S. Identification of CSF Biomarkers for the Diagnosis of CNS Lymphoma. Blood. 108: 2036-2036. DOI: 10.1182/Blood.V108.11.2036.2036 |
0.423 |
|
| 2005 |
Rubenstein JL, Treseler P, O'Brien JM. Pathology and genetics of primary central nervous system and intraocular lymphoma. Hematology/Oncology Clinics of North America. 19: 705-17, vii. PMID 16083831 DOI: 10.1016/J.Hoc.2005.05.012 |
0.441 |
|
| 2005 |
Shenkier TN, Blay JY, O'Neill BP, Poortmans P, Thiel E, Jahnke K, Abrey LE, Neuwelt E, Tsang R, Batchelor T, Harris N, Ferreri AJ, Ponzoni M, O'Brien P, Rubenstein J, et al. Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2233-9. PMID 15800313 DOI: 10.1200/Jco.2005.07.109 |
0.437 |
|
| 2004 |
Rubenstein JL, Shen A, Abrey L, Combs D, Haqq C, Damon L, O'Brien J, O'Connor P, Prados M, Shuman M. Results from a phase I study of intraventricular administration of rituximab in patients with recurrent lymphomatous meningitis Journal of Clinical Oncology. 22: 6593-6593. DOI: 10.1200/Jco.2004.22.90140.6593 |
0.439 |
|
| 2004 |
Shenkier T, Blay J, O’Neill BP, Poortmans P, Janke K, Abrey LE, Neuwelt E, Tsang R, Batchelor T, Harris N, Ferreri AJ, Ponzoni M, O’Brien P, Rubenstein J, Connors JM. Primary Central Nervous System Lymphoma of T Cell Origin: A Descriptive Analysis of 45 Cases from the International PCNSL Collaborative Group. Blood. 104: 1372-1372. DOI: 10.1182/Blood.V104.11.1372.1372 |
0.424 |
|
| 2003 |
Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, Grillo-Lopez A, Shuman MA. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 101: 466-8. PMID 12393404 DOI: 10.1182/Blood-2002-06-1636 |
0.486 |
|
| 2002 |
Rubenstein J, Fischbein N, Aldape K, Burton E, Shuman M. Hemorrhage and VEGF expression in a case of primary CNS lymphoma. Journal of Neuro-Oncology. 58: 53-6. PMID 12160141 DOI: 10.1023/A:1015887312455 |
0.409 |
|
| Show low-probability matches. |
